VITA 34 International AG: General Meeting approves all items on the agenda with more than 99 percent

VITA 34 International AG / AGM/EGM

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
The issuer / publisher is solely responsible for the content of this announcement.

Leipzig, 15 July 2009 - The shareholders of VITA 34 International AG (ISIN
DE000A0BL849), the holding company of the leading umbilical cord blood bank
within the German-speaking area VITA 34, have approved all the items on the
agenda with more than 99 percent during today's General Meeting of
shareholders. Among other things, the management and the supervisory board
were granted formal approval for the financial year 2008.

In addition, the General Meeting of shareholders resolved to reduce the
supervisory board from six to three members. Richard J. Neeson, Senior Vice
President of the corporation's principal shareholder Independence Blue
Cross and Dr. Uwe Marx, CSO of the Probiogen AG, were confirmed as members
of the supervisory board. Dr. Holger Födisch, CEO of the Dr. Födisch
Umweltmesstechnik AG, was newly elected as a member of the supervisory
board. A total of up to 69 percent of the share capital were present at the
General Meeting of shareholders.

Press/ Investor Relations:
Axel Mühlhaus
Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Phone: +49 (069) 90550550
Fax: +49 (069) 90550577

15.07.2009  Financial News transmitted by DGAP
Language:     English
Issuer:       VITA 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Hamburg, Stuttgart
End of News                                     DGAP News-Service